Comparative Pharmacology
Head-to-head clinical analysis: ACIPHEX versus NAPROXEN AND ESOMEPRAZOLE MAGNESIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACIPHEX versus NAPROXEN AND ESOMEPRAZOLE MAGNESIUM.
ACIPHEX vs NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Esomeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase pump in gastric parietal cells, decreasing gastric acid secretion.
20 mg orally once daily; duration: 4-8 weeks for erosive esophagitis, 4 weeks for GERD, 24 weeks for H. pylori eradication (triple therapy: AcipHex 20 mg + amoxicillin 1000 mg + clarithromycin 500 mg twice daily for 7 days), 4 weeks for duodenal ulcer, up to 12 months for pathological hypersecretory conditions.
One tablet (naproxen 500 mg / esomeprazole 20 mg) orally twice daily.
None Documented
None Documented
Plasma half-life 1-2 hours, but pharmacodynamic half-life (acid suppression) >24 hours due to accumulation in parietal cell canaliculi.
Naproxen: ~12-17 hours (allows twice-daily dosing). Esomeprazole: ~1-1.5 hours (no accumulation).
Hepatic metabolism, primarily via CYP2C19 and CYP3A4; ~90% eliminated as metabolites in urine, <1% unchanged; remainder in feces.
Naproxen: ~95% renal (as unchanged drug and conjugates), ~5% fecal. Esomeprazole: ~80% renal (as metabolites), ~20% fecal.
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor